clinical trial

[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)] Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.

[CRISPR Therapeutics, Inc.] CRISPR Therapeutics,Inc. and ViaCyte, Inc., announced that Health Canada has approved the companies’ Clinical Trial Application for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes. Initiation of patient enrollment is expected by year-end.

[Rakovina Therapeutics, Inc.] Rakovina Therapeutics, Inc. announced that the company has been selected to join a three year US $975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

[Nature Communications] The authors used a comprehensive panel of in vitro and in vivo assays to demonstrate that CX-5461 had been mischaracterized and that its primary target at pharmacologically relevant concentrations was topoisomerase II beta (TOP2B).

[Yumanity Therapeutics, Inc.] Yumanity Therapeutics, Inc. reported that its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled Phase Ib clinical trial in patients with mild-to-moderate Parkinson’s disease.

[TransThera Sciences] TransThera Sciences Inc. announced that the US FDA has granted Fast Track Designation to its Phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinom who have no standard treatment options.